<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560053</url>
  </required_header>
  <id_info>
    <org_study_id>PETHEMA MM-2000</org_study_id>
    <nct_id>NCT00560053</nct_id>
  </id_info>
  <brief_title>Pethema Multiple Myeloma 2000</brief_title>
  <official_title>Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objectives are to investigate the toxicity and the BUMEL response rate; in patients
      who reach the CR after autotransplantation, investigate if negativization of IF, influences
      in disease evolution; in patients in PR after autotransplantation, analyze if the second
      intensive procedure is capable of increasing the response rate and increasing the survival so
      that patients who reached the CR with the first transplantation; Patients with MM primarily
      resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients
      submitted to double transplantation, control the efficacy of the second transplantation in
      front of allogenic transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">500</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alternating chemotherapy</intervention_name>
    <description>4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.
VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Transplantation</intervention_name>
    <description>Autologous Transplantation :
BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance</intervention_name>
    <description>At 3 months of transplantation or with &gt;1.500 neutrophiles/ &gt; 75.000 platelets mm 3 .
Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Second transplantation</intervention_name>
    <description>In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ALOGENIC MINI TRASPLANTATION</intervention_name>
    <description>ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Less 70 years

          -  ECOG 0-2

          -  Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia,
             extramedulary plasmocytoma, creatinine &gt;2 mg/dl).

          -  No previous chemotherapy

        Exclusion Criteria:

          -  &gt;70 years

          -  ECOG 3-4

          -  myeloma quiescent

          -  cardiopathy

          -  liver disfunction

          -  HIV+

          -  Hepatitis B-C +

          -  Previous chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Bladé, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Jose Lahuerta, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Doce de Octubre Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrián Alegre, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital La Princesa Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Sureda, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Sant Pau Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquín Díaz Mediavilla, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinico Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier De la Rubia, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital La Fe de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Bargay, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Son Dureta Palma de Mallorca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose García-Laraña, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eulogio Conde, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Valdecilla Santander</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Prosper, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinico Valencia</affiliation>
  </overall_official>
  <link>
    <url>http://aehh.org</url>
    <description>spanish hematology association</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2007</study_first_posted>
  <last_update_submitted>November 26, 2008</last_update_submitted>
  <last_update_submitted_qc>November 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2008</last_update_posted>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Alternating chemotherapy</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

